In this article, we will look at the 14 Best Long-Term Penny Stocks to Buy Right Now.
On August 29, Ed Yardeni, President of Yardeni Research, appeared on CNBC’s ‘Closing Bell’ to talk about the latest news impacting markets, the possible factors that might inspire the next market surge, and more.
He stated that the market is feeling like a slow-motion melt-up, continually going higher and higher. The earnings story has been great, according to him, with Q1 earnings coming in better than expected.
The same thing happened in Q2, which Yardeni considers “remarkable” considering the uncertainty and turmoil from tariffs. Earnings have moved past these headwinds, and the US market appears to be back on its winning track.
READ ALSO: 13 High Growth Low PE Stocks to Invest In Now and 15 Strong Buy Stocks Under $5 to Buy Now.
He added that the market loves Fed puts, so if we get a Fed put and the economy doesn’t really need it, that would result in further melt-up.
The overall outlook is that we are in a bull market right now, with a tremendous amount of buying power and lots of buying on the dips.
With these trends in view, let’s look at the best long-term penny stocks to buy right now.
Our Methodology
We used Finviz to compile an initial list of top stocks with a 5-year revenue growth above 10% and a stock price under $5. We then selected the top 14 stocks with the highest number of hedge fund holders as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Note: All data was recorded on August 29.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
14 Best Long-Term Penny Stocks to Buy Right Now
14. ImmunityBio, Inc. (NASDAQ:IBRX)
Stock Price: $2.33
5-Year Revenue Growth Rate: 46.27%
Number of Hedge Fund Holders: 14
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best long-term penny stocks to buy right now. On August 26, ImmunityBio, Inc. (NASDAQ:IBRX) announced the early findings of the first five recurrent glioblastoma patients that were treated with its investigational immune-boosting regimen, including ANKTIVA, in this pilot study.
The company reported that all five patients attained 100% disease control with the regimen that “combines ANKTIVA, an IL-15 agonist being studied for its ability to enhance natural killer (NK) cell activity, NK cell therapy (PD-L1 t-haNK), and Optune Gio Tumor Treating Fields.”
The study showed that the ANKTIVA treatment raised absolute lymphocyte count (ALC) in all five patients who had experienced lymphopenia after standard of care radiation and chemotherapy.
Management stated that the results were highly encouraging, with “5 out of 5 (100%) disease control in 2nd line recurrent glioblastoma receiving a chemotherapy-free immunotherapy with Optune immune-stimulating device.”
Based on these initial findings, ImmunityBio, Inc. (NASDAQ:IBRX) is starting a “randomized trial targeting second-line GBM patients who have recurring disease following standard of care.”
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.
13. Silvercorp Metals, Inc. (NYSE:SVM)
Stock Price: $4.64
5-Year Revenue Growth Rate: 14.01%
Number of Hedge Fund Holders: 15
Silvercorp Metals, Inc. (NYSE:SVM) is one of the best long-term penny stocks to buy right now. Silvercorp Metals, Inc. (NYSE:SVM) reported its fiscal Q1 2026 results on August 7, producing approximately 1.8 million ounces of silver, 2,050 oz of gold, or around 2.0 million ounces of silver equivalent, 15.7 million pounds of lead, and 5.2 million lb of zinc.
The company also announced that it sold around 1.8 million oz of silver, 1,951 oz of gold, 15.2 million lb of lead, and 5.2 million lb of zinc, with the revenue reaching $81.3 million.
On August 7, Raymond James analyst Craig Stanley raised the firm’s price target on Silvercorp Metals, Inc. (NYSE:SVM) to C$8 from C$7.50, keeping an Outperform rating on the shares.
Similarly, Roth MKM analyst Joseph Reagor maintained a Buy rating on Silvercorp Metals, Inc. (NYSE:SVM) on August 11 and set a price target of $6.50.
The stock’s median price target of $4.64 implies an upside of 32.26% from current levels.
Silvercorp Metals (NYSE:SVM) is a Canadian mining company that produces gold, silver, lead, and zinc. It operates several silver-lead-zinc mines in China, including the Ying Mining District in Henan Province and the GC silver-lead-zinc mine in Guangdong Province.
While the company’s producing mines are in China, its development and exploration projects are in Mexico and China.